What is the prevalence of Antiphospholipid / Hughes Syndrome?

Antiphospholipid syndrome (APS), also known as Hughes syndrome, is estimated to affect approximately 1 in 2,000 individuals in the general population, though precise figures remain difficult to determine due to frequent underdiagnosis. It is characterized by an increased risk of blood clots and pregnancy complications, with a significantly higher prevalence observed in women, particularly those with underlying autoimmune conditions like systemic lupus erythematosus.

How common is Antiphospholipid / Hughes Syndrome?

Antiphospholipid / Hughes syndrome is classified as a rare disease. While the estimated prevalence is roughly 50 cases per 100,000 people, these numbers are likely conservative. Many individuals remain asymptomatic until a major thrombotic event occurs, leading to significant underdiagnosis. Within the DiseaseMaps.org community, we have seen 451 members join to share their experiences with Antiphospholipid / Hughes syndrome, reflecting the global reach and the lived reality of those navigating this complex condition.

What are the gender and age distribution patterns?

There is a distinct gender disparity in the diagnosis of Antiphospholipid / Hughes syndrome. Studies consistently show that women are affected significantly more often than men, with some clinical cohorts reporting a female-to-male ratio as high as 5:1. Regarding age of onset, the condition is most commonly diagnosed in young to middle-aged adults, typically between the ages of 20 and 50. While pediatric cases of Antiphospholipid / Hughes syndrome do occur, they are significantly less common and often associated with infections or severe systemic autoimmune flares.

Are there geographic or ethnic variations in prevalence?

Data regarding the geographic or ethnic prevalence of Antiphospholipid / Hughes syndrome is limited. Because the condition is often secondary to other autoimmune diseases, regions with higher rates of lupus may report higher localized instances of Antiphospholipid / Hughes syndrome. However, there is no definitive evidence to suggest the syndrome is tied to a specific ancestry or geographic location, and it is recognized as a global health concern.

Why is accurate prevalence data challenging to obtain?

Determining the exact number of people living with Antiphospholipid / Hughes syndrome is complicated by several factors:

• Asymptomatic carriers: Many people carry antiphospholipid antibodies without ever manifesting clinical symptoms like thrombosis or pregnancy loss.


• Diagnostic delays: The symptoms of Antiphospholipid / Hughes syndrome are diverse and can mimic other vascular or neurological conditions, often leading to years of misdiagnosis.


• Variable criteria: Changes in clinical classification criteria over the decades have made it difficult to compare historical data with modern epidemiological findings.

Next steps

• Consult a rheumatologist or a hematologist specializing in coagulation disorders for a comprehensive evaluation.


• Join the DiseaseMaps.org community to connect with other patients and share your journey with Antiphospholipid / Hughes syndrome.


• Keep a detailed log of any unexplained clotting events or pregnancy complications to assist your medical team in the diagnostic process.


• Check the NIH GARD website or the Hughes Syndrome Foundation for the latest updates on clinical trials and research.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• Orphanet: Antiphospholipid syndrome (ORPHA:79287)


• NIH Genetic and Rare Diseases Information Center (GARD): Antiphospholipid syndrome


• OMIM: Antiphospholipid syndrome (Entry #600869)


• Hughes Syndrome Foundation: Understanding the condition and patient resources